Saturday 17 October 2026
Export MENS’s income statement to Excel — free account
Jyong Biotech Ltd.
MENS Healthcare Biotechnology
1.84
0.14
−7.07%
Follow MENS
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 2.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 67.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 29 | 27 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | (4) | (3) | (5) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (4) | (3) | (5) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (0.06) | (0.04) | (0.06) | |||||
| Cash flow | — | — | — | — | — | — | — | (0.04) | (0.05) | (0.04) | |||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | (0.04) | (0.05) | (0.04) | |||||
| Book value | — | — | — | — | — | — | — | (0.48) | (0.51) | (0.34) | |||||
| Shares, m | — | — | — | — | — | — | — | 72 | 72 | 73 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (3) | (4) | (3) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | (3) | (4) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (12) | (12) | (19) | ||||
| Total debt | — | — | — | — | — | — | — | 16 | 18 | 18 | |||||
| Net debt | — | — | — | — | — | — | — | 15 | 18 | 17 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (34) | (37) | (25) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (41.32) | (34.42) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 8.55 | 15.21 | |||||
Negative figures in brackets.
Charts ten years each
Jyong Biotech Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NBP NovaBridge Biosciences | $149.6M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNTN Canton Strategic Holdings, Inc. | $149.0M | 9.0× | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| CDXS Codexis, Inc. | $148.9M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| MENS Jyong Biotech Ltd. | $147.0M | — | — | — | — | — | — | — | |
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NKTX Nkarta, Inc. | $138.2M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $144.3M | — | — | −93.70% | — | −2.17% | 38.23% | 0.00% |
Jyong Biotech Ltd. (MENS) key facts
- Concern: Jyong Biotech Ltd. reported a net loss of $4.7 million, or a loss of $0.06 per share, for fiscal 2025.
- Jyong Biotech Ltd. (MENS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MENS traded at $1.84, a market capitalization of $147.0 million.
- Return on equity was 15.2% and debt-to-equity -0.74.
Jyong Biotech Ltd. (MENS) Latest News
No news at this impact. Lower the threshold for more.